Clinical trial · Interventional
Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
Collection of Biological Samples for Research Purposes: Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
NCT07250217CI-TRIAL-00102433LAMMErecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloblastic Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epigenetic markers | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- AML
- description
- Elderly patients diagnosed with acute myeloid leukemia. An additional volume of blood (10 mL) and bone marrow (2 mL) will be collected during follow-up visits as part of their routine care.
- interventionNames
- Diagnostic Test: Epigenetic markers
- type
- OTHER
- label
- Control group
- description
- Elderly patients scheduled for thoracic surgery involving sternotomy. A bone marrow sample (2 mL) will be obtained by sternal puncture in the operating room (after general anesthesia and before sternotomy), and an additional blood sample (10 mL) will be collected during the hospital stay.
- interventionNames
- Diagnostic Test: Epigenetic markers
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
1. / Control Group Inclusion Criteria: * Age ≥ 60 years; * Scheduled for cardiac surgery involving sternotomy; * Normal blood count within the two months preceding sampling; * Affiliated with, or beneficiary of, a social security system; * Written informed consent to participate in the study. Exclusion Criteria: * Patients deemed unsuitable for sampling by the surgeon performing the procedure; * Patients under legal protection measures; * Patients under judicial supervision or deprived of liberty by judicial or administrative decision; * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV). 2. / AML Group Inclusion Criteria: * Age ≥ 60 years; * Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment; * Affiliated with, or beneficiary of, a social security system; * Written informed consent to participate in the study. Exclusion Criteria: * Diagnosis of a hematologic disease other than AML; * Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia; * Previous treatment for AML other than hydroxyurea; * Severe comorbidities that could interfere with the study, as assessed by the principal investigator; * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV); * Patients under legal protection; * Patients under judicial supervision or deprived of liberty by judicial or administrative decision.
References
Publications (0)
Data not yet available
No reference posted for this study.